Understanding how aging cells in tumors affect cancer immunity and growth
Official title: Stomal Senescence Regulator of Tumor Immunity and Progression
Funded at Washington University · NIH-10776941 · Data updated 2026-11-12
This study is looking at how aging cells in pancreatic cancer tumors affect the immune system and the growth of the cancer, with the hope of finding new ways to improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $648,846 |
| NIH project number | 1R01CA286615-01 |
| Project ID | NIH-10776941 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma (PDAC) who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with pancreatic cancer may not benefit from this research.
What this research studies
This research investigates the role of cellular aging within the tumor environment of pancreatic cancer, specifically how it influences immune responses and tumor progression. By examining different types of cancer-associated fibroblasts, the study aims to identify how these cells can either support or hinder tumor growth. The approach involves advanced biophysical and immunological techniques to analyze the tumor microenvironment and its impact on treatment resistance. Patients may benefit from insights that could lead to new therapeutic strategies targeting these aging cells.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance the immune response against pancreatic cancer.
How similar studies have gone: While the specific approach of targeting stromal senescence in pancreatic cancer is relatively novel, similar strategies in other cancers have shown promising results.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.